$ACRS

2 stories mentioning ACRSUpdated 89d ago

Every FINWIRES story that references ACRS, newest first.

Aclaris Therapeutics Insider Sold Shares Worth $1,359,000, According to a Recent SEC Filing

Braden Michael Leonard, 10% Owner, on April 27, 2026, sold 300,000 shares in Aclaris Therapeutics (ACRS) for $1,359,000. Following the Form 4 filing with the SEC, Leonard has control over a total of 13,950,000 common shares of the company, with 13,950,000 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1557746/000137360426000034/xslF345X05/form4.xml

$ACRS

Research114d ago

Oppenheimer Initiates Aclaris Therapeutics at Outperform With $10 Price Target

Aclaris Therapeutics (ACRS) has an average rating of buy and mean price target of $8.94, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)

$ACRS

Track with the FINWIRES app suite

FolioX

Track ACRS in your portfolio

WheelAI

Analyze ACRS options with the wheel strategy

StockInsider

See market sentiment on ACRS